A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

NCT02519439 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
26
Enrollment
INDUSTRY
Sponsor class

Stopped Ganaxolone missed its primary endpoint in the double-blind portion of the 1042-0603 study. Due to this outcome Marinus discontinued this extension study.

Conditions

Interventions

Sponsor

Marinus Pharmaceuticals